{"entity":{"id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","aka":[],"tldr":"A phase 2 trial of Intismeran autogene, Pembrolizumab in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). is a phase 2 interventional study registered as NCT06307431 by Merck Sharp & Dohme LLC, with 272 participants planned, started 2024-04-10 and due to reach its primary completion in 2028-01-08. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06307431","url":"https://clinicaltrials.gov/study/NCT06307431"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["intismeran-autogene","pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06307431","phase":"2","setting":"A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).","sponsor":"Merck Sharp & Dohme LLC","enrolled":272,"outcomes":[]},"route":"/trials/nct06307431/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}